Lupisit D 5mg/100mg Tablet is a combination oral antidiabetic medication containing dapagliflozin 5mg and sitagliptin 100mg, indicated for the management of type 2 diabetes mellitus. Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, works by reducing glucose reabsorption in the kidneys, thereby promoting urinary glucose excretion and lowering blood glucose levels. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances incretin hormone activity, leading to increased insulin secretion and decreased glucagon release in a glucose-dependent manner. The combination of these agents provides complementary mechanisms to improve glycemic control in patients inadequately controlled by diet and exercise alone. Lupisit D is typically prescribed as an adjunct to lifestyle modifications and may be used as monotherapy or in combination with other antidiabetic agents. It is important to monitor renal function prior to and during treatment due to dapagliflozin’s renal mechanism of action. Common adverse effects include urinary tract infections, genital mycotic infections, and nasopharyngitis. Caution is advised in patients with a history of hypersensitivity to either component, and it is contraindicated in type 1 diabetes and diabetic ketoacidosis. Regular monitoring of blood glucose and HbA1c levels is recommended to assess therapeutic efficacy.